COHBAR, INC. (OTCMKTS:CWBR) Files An 8-K Other EventsItem 8.01 Other Matters
On November 5, 2018, CohBar, Inc. issued a press release announcing that its Phase 1 clinical study of CB4211, its lead MBT candidate, has been temporarily suspended to address injection site reactions.
Item 8.01 Financial Statements and Exhibits
(d) Exhibits
The following exhibit is furnished herewith and this list is intended to constitute the exhibit index:
| 99.1 | CohBar, Inc. press release dated November 5, 2018. |
CohBar, Inc. ExhibitEX-99.1 2 f8k110518ex99-1_cohbar.htm COHBAR,…To view the full exhibit click here
